Arthrogryposis–Renal Dysfunction–Cholestasis (ARC) Syndrome 

Arthrogryposis–renal dysfunction–cholestasis (ARC) syndrome is a very rare, inherited (autosomal recessive) condition that starts at birth. The classic triad is: (1) arthrogryposis—stiff joints and contractures present from birth; (2) renal (kidney) dysfunction—especially problems with the kidney tubules that cause salt and acid–base imbalance; and (3) cholestasis—poor bile flow from the liver leading to jaundice and intense itching. Other common features include poor growth, dry/scaly skin (ichthyosis), platelet problems that can cause bleeding, brain and nerve differences, frequent infections, and feeding difficulties. ARC is usually caused by harmful variants (mutations) in one of two genes—VPS33B or VIPAS39 (also called VIPAR)—which act together in cells to keep proteins moving to the right places. When these genes do not work, many organs lose polarity and trafficking control, so multiple systems are affected. Most children have severe disease, although milder, longer-surviving cases are reported. Rare Diseases +3PMC+3PMC+3

Inside our cells, proteins and fats are constantly packed into tiny “bubbles” (vesicles) and delivered to precise addresses on the cell surface. VPS33B and VIPAS39/VIPAR form a complex that helps this delivery system, working with partners like RAB11A and the HOPS/CORVET machinery. If VPS33B or VIPAS39 is faulty, cells (especially in liver, kidney, and skin) lose their normal “top/bottom” polarity. In the liver this can block bile movement (cholestasis); in kidney tubules it disrupts channels that reclaim salts and bicarbonate; in skin it impairs barrier function causing ichthyosis; and in platelets it causes α-granule defects and bleeding risk. The result is a multisystem disease. There is currently no cure; treatment focuses on symptom control and preventing complications. BioMed Central+2Oxford Academic+2

ARC syndrome is a rare, inherited condition that affects many organs from birth or early infancy. The name comes from its three main problems:

• Arthrogryposis: very stiff joints and tight muscles at birth.

• Renal (kidney) dysfunction: the kidney tubes leak important salts, sugars, and minerals, causing dehydration and acidosis.

• Cholestasis: the liver cannot move bile properly, leading to jaundice and itching. In ARC, a lab clue is low or normal GGT (a liver enzyme), which helps doctors think about ARC and similar disorders. Most babies show symptoms in the newborn period. The illness can be severe and may be life-limiting, although milder forms exist. ARC is autosomal recessive, meaning a child is affected when they inherit a faulty copy of the gene from both parents. BioMed Central+3NCBI+3BioMed Central+3

---

Other names

• ARC syndrome

• ARCS or ARCS1/ARCS2 (subtypes explained below)

• Arthrogryposis–renal dysfunction–cholestasis syndrome

• Sometimes described as “low-GGT cholestasis with renal tubular dysfunction and arthrogryposis.” Genetic Rare Disease Center+1

ARC syndrome happens when there are disease-causing changes (variants) in one of two genes that control cellular trafficking—the way cells sort and deliver proteins to the right place:

1. VPS33B (most cases; often termed ARCS1)

2. VIPAS39 (also called VIPAR; termed ARCS2)

These two proteins work together in a trafficking system related to the HOPS tethering machinery. When they do not work, cells lose normal apical–basolateral polarity and cannot package and deliver key proteins. In the liver, bile cannot be secreted well (cholestasis with low/normal GGT). In the kidney, tubules leak glucose, amino acids, phosphate, and bicarbonate (a Fanconi-like picture). In the skin, the outer layer cannot release normal lipids (ichthyosis). Platelets may lack alpha-granules, causing easy bruising. These are all different faces of the same basic trafficking problem. ScienceDirect+3NCBI+3Oxford Academic+3

---

Types

• Classical ARC (ARCS1 or ARCS2): typical triad (arthrogryposis, renal tubular dysfunction, low-GGT cholestasis) with frequent extra findings such as ichthyosis, growth failure, bleeding problems, and infections. Sadly, many infants with classical ARC have a poor prognosis. BioMed Central

• Attenuated / milder ARC: some children have few or later symptoms. For example, rare VPS33B or VIPAS39 variants can present with cholestasis (sometimes isolated low-GGT cholestasis) or milder kidney and joint issues. Survival can be longer. The milder spectrum is increasingly recognized now that genetic testing is more common. PubMed+3Wiley Online Library+3Wiley Online Library+3

---

Causes

ARC is a genetic disorder; “causes” here means the genetic and biological reasons it develops and the factors that make features worse or milder.

1. Biallelic VPS33B variants (ARCS1): the main genetic cause worldwide. Different variant types (missense, nonsense, frameshift, splice) all reported. NCBI

2. Biallelic VIPAS39 (VIPAR) variants (ARCS2): the second well-established gene. NCBI

3. Loss of VPS33B–VIPAS39 complex function: the two proteins normally bind; disease variants disrupt complex formation or localization. PubMed

4. Defective HOPS-related endosomal maturation/fusion: trafficking steps stall, so proteins don’t reach their apical targets. Oxford Academic

5. Loss of apical–basolateral polarity in hepatocytes: bile canalicular proteins mis-sorted → cholestasis with low/normal GGT. NCBI

6. Impaired apical transporters in renal tubules: causes Fanconi-like leaks (glucose, phosphate, amino acids, bicarbonate). BioMed Central

7. Defective lamellar body secretion in skin: leads to ichthyosis and barrier dryness. ScienceDirect

8. Platelet alpha-granule deficiency: abnormal trafficking in megakaryocytes → easy bruising/bleeding. BioMed Central

9. Neurogenic arthrogryposis: prenatal reduced movement from neuromuscular involvement → fixed joints at birth. Genetic Rare Disease Center

10. Consanguinity (parents related): increases the chance both parents carry the same rare variant. PGHN

11. Founder effects in some populations: same variant seen repeatedly in a region/family. (Documented in several case clusters.) Frontiers

12. Variant-specific effects: some changes cause milder trafficking defects and milder disease. Wiley Online Library

13. Modifier genes (suspected): other genes for low-GGT cholestasis pathways may influence severity. (Evidence from broader low-GGT cholestasis literature.) Lippincott Journals

14. Prematurity/illness stress: may unmask or worsen electrolyte and growth problems in infancy. (Clinical inference consistent with case series.) BioMed Central

15. Dehydration episodes: worsen renal tubular acidosis and salt loss. (General ARC management discussions.) VisualDx

16. Infections: frequent in ARC and may aggravate liver and kidney stress. BioMed Central

17. Poor nutrition / failure to thrive: due to malabsorption, catabolism, and feeding difficulty, worsening outcomes. BioMed Central

18. Unrecognized mild ARC: late or missed diagnosis delays supportive care. (Emphasized in newer VIPAS39 studies.) PubMed

19. Platelet dysfunction with bleeding: increases risk during procedures and illness. BioMed Central

20. Limited disease-specific therapy: there is no curative treatment yet; care is supportive, which influences prognosis. PMC

---

Common symptoms and signs

1. Stiff joints at birth (arthrogryposis): arms and legs do not move or bend easily. BioMed Central

2. Yellow skin or eyes (jaundice) from cholestasis. Often starts early. GGT is low/normal on labs. NCBI

3. Severe itching because bile salts build up in the skin. NCBI

4. Poor weight gain and growth failure (failure to thrive). BioMed Central

5. Dry, scaly skin (ichthyosis). ScienceDirect

6. Dehydration: from kidney salt and water loss. BioMed Central

7. Frequent urination and excessive thirst from kidney tubular leaks. BioMed Central

8. Metabolic acidosis: fast breathing, irritability, or sleepiness when acids build up. BioMed Central

9. Bone weakness / rickets signs (bowed legs, bone pain) from phosphate and vitamin D loss. BioMed Central

10. Easy bruising or bleeding from platelet storage pool problems. BioMed Central

11. Infections that come back often. BioMed Central

12. Feeding problems, vomiting, or poor appetite. BioMed Central

13. Developmental delay (some children). Frontiers

14. Hearing loss (some children) found on newborn screening or later tests. Frontiers

15. Tiredness and weakness due to anemia, acidosis, or poor nutrition. BioMed Central

---

Diagnostic tests

A) Physical examination (bedside checks)

1. Joint and posture check: doctor looks for fixed joints, clubfoot, or limited movement that point to arthrogryposis. BioMed Central

2. Skin check: dry, scaly skin suggests ichthyosis common in ARC. ScienceDirect

3. Jaundice check: yellow eyes/skin and scratch marks from itching suggest cholestasis. NCBI

4. Growth and nutrition review: weight, length, head size to document failure to thrive. BioMed Central

5. Hydration status: dry mouth, sunken eyes, low tears suggest salt/water loss from kidneys. BioMed Central

B) Manual/functional tests (simple bedside maneuvers and measurements)

6. Range-of-motion testing for each limb: documents how stiff or flexible joints are and guides therapy. BioMed Central

7. Hip stability maneuvers (Ortolani/Barlow): check for hip contracture or dislocation common in arthrogryposis. BioMed Central

8. Neuromuscular tone and reflexes: looks for low or high tone that can go with neurogenic arthrogryposis. Genetic Rare Disease Center

9. Scratch test / pruritus assessment: simple scoring of itching burden to monitor bile-related itch. NCBI

10. Feeding evaluation (suck/swallow): identifies feeding difficulty contributing to poor growth. BioMed Central

C) Laboratory & pathological tests

11. Liver panel with GGT: conjugated bilirubin high, transaminases high; GGT low/normal is a key clue for ARC-type cholestasis. NCBI

12. Serum bile acids: high in cholestasis and help track itch response. NCBI

13. Electrolytes and blood gas: shows metabolic acidosis from kidney bicarbonate loss; potassium/sodium changes. BioMed Central

14. Urinalysis with glucose/amino acids/phosphate: detects Fanconi-like leaks (glucosuria with normal blood sugar, aminoaciduria, phosphaturia). BioMed Central

15. Vitamin D, calcium, alkaline phosphatase: screens for rickets/osteomalacia from phosphate loss. BioMed Central

16. Coagulation profile and platelet studies: may show platelet storage-pool problems (alpha-granule deficiency) and bleeding risk. BioMed Central

17. Genetic testing panel or exome for VPS33B and VIPAS39 variants: confirms the diagnosis and can predict classical vs milder disease. Frontiers+1

18. Liver biopsy (select cases): can show cholestasis patterns; today often avoided if genetics is clear. PMC

D) Electrodiagnostic / physiologic tests

19. Newborn hearing screen / Auditory Brainstem Response (ABR): checks for the hearing loss reported in some children with ARC. Frontiers

20. ECG or cardiac monitoring during severe electrolyte problems: safety check when potassium or acid–base is abnormal from kidney losses. (Supportive practice in ARC care.) VisualDx

E) Imaging (often done alongside the tests above)

• Abdominal ultrasound: looks at liver and bile ducts; rules out blockage; tracks liver size and texture.

• MRCP (magnetic resonance cholangiopancreatography): if anatomy needs closer review.

• Renal ultrasound: assesses kidney size and structure.
  (These are standard images used when evaluating neonatal cholestasis and renal tubular disorders in ARC.) BioMed Central

Non-pharmacological treatments (therapies & others)

(Each item includes a plain description, purpose, and mechanism in brief, all tailored to ARC.)

1. Gentle range-of-motion physiotherapy
   Description: Daily, gentle stretching and positioning to keep joints as flexible as possible, prevent contractures from worsening, and support motor milestones. Purpose: Reduce pain and stiffness, improve feeding posture and caregiver handling. Mechanism: Repeated low-load stretching remodels connective tissues and preserves muscle–tendon length; better alignment lowers shear on fragile skin. Rare Diseases

2. Occupational therapy with splinting
   Description: Custom soft splints and activity-based therapy to aid positioning, feeding, and grasp. Purpose: Improve function in daily tasks and reduce deformity progression. Mechanism: External support applies corrective forces over time; task-specific practice builds neuro-motor patterns despite contractures. Rare Diseases

3. Skin care for ichthyosis (emollients, humidification)
   Description: Liberal emollients, short lukewarm baths, fragrance-free cleansers, room humidification, nail care. Purpose: Reduce cracking, infections, and itching. Mechanism: Occlusive moisturizers restore barrier lipids and reduce transepidermal water loss; less dryness means fewer itch signals. PMC

4. Pruritus comfort measures
   Description: Cool rooms, loose cotton clothing, menthol/cooling gels, oatmeal soaks, distraction techniques; caregiver nail trimming to reduce scratching injury. Purpose: Ease cholestatic itch and protect skin. Mechanism: Cooling counter-stimulates itch pathways; mechanical protection prevents excoriations and infection. AASLD

5. Enteral nutrition optimization (high-calorie feeds)
   Description: Calorie-dense feeds using medium-chain triglyceride (MCT) formulations when fat malabsorption is present; frequent, small feeds; consider feeding tube if needed. Purpose: Support growth and immune function. Mechanism: MCTs are absorbed directly via portal vein without micelles, bypassing bile-dependent fat absorption. Rare Diseases

6. Fat-soluble vitamin monitoring protocol (A, D, E, K)
   Description: Regular lab checks and dietitian-guided supplementation plan. Purpose: Prevent rickets, neuropathy, vision issues, and bleeding. Mechanism: Replacing vitamins lost because of poor bile flow maintains bone mineralization, antioxidant defenses, and coagulation. PMC

7. Electrolyte & fluid planning (with nephrology)
   Description: Daily plans for fluids, sodium, potassium, bicarbonate/citrate intake; home logs for urine output and weight. Purpose: Prevent dehydration, metabolic acidosis, and arrhythmia risk. Mechanism: Matching tubular losses stabilizes extracellular volume and acid–base balance. PMC

8. Feeding/airway therapy (speech–language pathology)
   Description: Swallow evaluation, safe-feeding positions, thickened feeds if aspirating. Purpose: Prevent aspiration pneumonia and improve caloric intake. Mechanism: Compensatory strategies decrease penetration into airway and improve bolus control in hypotonia/contractures. Rare Diseases

9. Infection-prevention bundle
   Description: Hand hygiene, skin integrity checks, vaccination schedule adherence (per local guidance), early evaluation for fever. Purpose: Reduce sepsis risk in a medically fragile infant. Mechanism: Barrier protection and timely immunization lower pathogen exposure and severity. Rare Diseases

10. Developmental care (neonatal/infant programs)
    Description: Sensory-appropriate positioning, cue-based care, caregiver coaching. Purpose: Support neurodevelopment despite illness burden. Mechanism: Minimizing stress and optimizing sleep–wake cycles promotes brain plasticity. Rare Diseases

11. Bleeding-risk safety plan
    Description: Gentle handling, soft toothbrushes, pressure after heel sticks, rapid care for bruising. Purpose: Mitigate platelet-granule–related bleeding problems. Mechanism: Fewer minor traumas reduce mucocutaneous bleeding events. PMC

12. Thermoregulation and hydration coaching
    Description: Teach caregivers to avoid overheating and to monitor diapers/weights. Purpose: Prevent pruritus flares and dehydration. Mechanism: Heat worsens itching; proactive fluid strategies offset renal losses. AASLD

13. Care coordination & genetics counseling
    Description: Multidisciplinary clinic; education on inheritance and recurrence risks. Purpose: Family planning and consistent, streamlined care. Mechanism: Early genetic confirmation enables targeted surveillance and informed decisions. BioMed Central

14. Positioning devices & pressure-relief
    Description: Cushions, wedges, and careful turning schedules. Purpose: Prevent pressure sores on fragile, pruritic skin. Mechanism: Pressure redistribution maintains skin perfusion. PMC

15. Itch-focused behavioral strategies
    Description: Gentle massage, distraction, play, soothing routines. Purpose: Reduce scratching cycles and improve sleep. Mechanism: Competing sensory input and conditioned routines modulate itch perception. AASLD

16. Bone health support (physio + nutrition)
    Description: Weight-bearing as tolerated, vitamin D/calcium optimization. Purpose: Counter rickets and osteopenia in cholestasis. Mechanism: Mechanical loading plus vitamin repletion improves bone mineralization. PMC

17. Dental/oral care planning
    Description: Early pediatric dental input; manage bleeding risk. Purpose: Prevent caries/bleeding with safe techniques. Mechanism: Anticipatory guidance reduces invasive emergencies. PMC

18. Family psychosocial support
    Description: Social work, respite care, mental-health support. Purpose: Reduce caregiver burnout and improve adherence. Mechanism: Lower stress improves caregiving capacity and child outcomes. Rare Diseases

19. Palliative care integration
    Description: Symptom-focused care alongside active treatment, from diagnosis. Purpose: Optimize comfort and family goals-of-care. Mechanism: Structured symptom assessment and anticipatory guidance reduce distress. Rare Diseases

20. Transition planning for survivors with milder disease
    Description: School supports, disability accommodations, long-term nephro-hepatic monitoring. Purpose: Promote independence and safety. Mechanism: Early, proactive planning prevents gaps in chronic care. Frontiers

---

Drug treatments

These medicines target symptoms (itch, cholestasis complications, kidney tubular losses, bleeding risk, nutrition). Doses below are typical pediatric starting points from general guidance; exact dosing must be individualized by the child’s specialists.

1. Cholestyramine (bile-acid sequestrant)
   Class: Anion-exchange resin. Dose/Time: ~240 mg/kg/day divided 2–4 doses (max 8–12 g/day), given away from other meds and vitamins. Purpose: First-line for cholestatic itch. Mechanism: Binds bile acids in gut to reduce re-circulation; fewer pruritogens reach blood. Side effects: Constipation, bloating; reduces absorption of fat-soluble vitamins and other drugs—separate by ≥4 h. AASLD+1

2. Rifampin
   Class: Enzyme inducer antibiotic. Dose/Time: ~5–10 mg/kg/day in 1–2 doses. Purpose: Second-line for refractory pruritus. Mechanism: Induces liver enzymes and pregnane X receptor pathways that lower pruritogens. Side effects: Hepatotoxicity risk, drug interactions, orange body fluids—requires monitoring. AASLD+1

3. Naltrexone
   Class: Opioid antagonist. Dose/Time: ~0.5–1 mg/kg/day. Purpose: Third-line for itch when others fail. Mechanism: Blocks central/opioid-mediated itch pathways unbalanced in cholestasis. Side effects: Withdrawal-like symptoms in opioid-exposed patients, nausea; monitor LFTs. AASLD+1

4. Sertraline
   Class: SSRI. Dose/Time: ~0.5–2 mg/kg/day. Purpose: Adjunct for refractory pruritus and pruritus-related anxiety/sleep disturbance. Mechanism: Modulates central itch perception. Side effects: GI upset, activation, hyponatremia; slow titration. Frontiers

5. Ursodeoxycholic acid (UDCA)
   Class: Hydrophilic bile acid. Dose/Time: 10–20 mg/kg/day divided BID–TID. Purpose: Support bile flow in some cholestatic diseases; variable benefit in ARC. Mechanism: Replaces toxic bile acids, cytoprotective effects. Side effects: Diarrhea; monitor liver tests. PMC

6. Vitamin K (phytomenadione)
   Class: Fat-soluble vitamin. Dose/Time: As per labs; often parenteral or high-dose oral. Purpose: Prevent/treat bleeding from malabsorption. Mechanism: Restores γ-carboxylation of clotting factors. Side effects: Rare anaphylactoid reactions with IV; monitor INR. PMC

7. Vitamin D (cholecalciferol/ergocalciferol) ± calcifediol
   Class: Fat-soluble vitamin. Dose/Time: Deficiency protocols per pediatric liver guidelines; sometimes water-miscible forms. Purpose: Prevent rickets/osteomalacia. Mechanism: Improves calcium absorption and bone mineralization. Side effects: Hypercalcemia if overdosed; monitor 25-OH D and calcium. PMC

8. Vitamin E (tocopherol) in water-soluble form
   Class: Antioxidant vitamin. Dose/Time: Specialized pediatric formulations; lab-guided. Purpose: Prevent neuropathy/hemolysis from deficiency. Mechanism: Membrane antioxidant. Side effects: Bleeding risk at very high doses; monitor levels. PMC

9. Vitamin A
   Class: Fat-soluble vitamin. Dose/Time: Lab-guided replacement. Purpose: Protect vision and epithelial health. Mechanism: Retinoid signaling for vision/skin. Side effects: Hepatotoxicity with overdose; careful monitoring. PMC

10. Sodium bicarbonate or sodium/potassium citrate
    Class: Alkali therapy. Dose/Time: Titrated to keep serum bicarbonate normal. Purpose: Treat metabolic acidosis from renal tubular losses. Mechanism: Buffers acid and replaces lost alkali. Side effects: GI upset, sodium load; lab monitoring needed. PMC

11. Electrolyte supplements (NaCl, K⁺, phosphate, Mg²⁺)
    Class: Replacement therapy. Dose/Time: Individualized per labs and urine losses. Purpose: Stabilize volume, prevent arrhythmias, support growth. Mechanism: Direct replacement of tubular losses. Side effects: Over- or under-correction risks; close monitoring. PMC

12. Medium-chain triglyceride (MCT) formulas
    Class: Specialized nutrition. Dose/Time: As diet composition under dietitian guidance. Purpose: Improve fat and calorie absorption. Mechanism: Bile-independent absorption. Side effects: GI intolerance in some; balance essential fatty acids. Rare Diseases

13. Iron ± folate (if deficient)
    Class: Hematinics. Dose/Time: Standard pediatric dosing per labs. Purpose: Correct anemia due to poor intake or chronic disease. Mechanism: Supplies substrates for erythropoiesis. Side effects: GI upset, constipation (iron); avoid excess. PMC

14. Antipruritic adjuncts: hydroxyzine at night
    Class: Antihistamine. Dose/Time: Weight-based at bedtime. Purpose: Sedation and partial itch relief to improve sleep. Mechanism: H1 blockade reduces histamine-mediated itch; sedative effect helps rest. Side effects: Drowsiness, anticholinergic effects. AASLD

15. Cholestasis-related antibiotics when indicated
    Class: Targeted per culture/clinical suspicion. Dose/Time: Per pediatric infectious-disease guidance. Purpose: Treat infections promptly in fragile infants. Mechanism: Pathogen eradication. Side effects: Drug-specific; stewardship is key. Rare Diseases

16. Proton-pump inhibitor or H2 blocker (if reflux/erosions)
    Class: Acid suppression. Dose/Time: Pediatric dosing as needed. Purpose: Protect esophagus, improve feeding comfort. Mechanism: Lowers gastric acid. Side effects: Infection risk, nutrient absorption effects with long-term use. Rare Diseases

17. Ondansetron (selected cases)
    Class: 5-HT3 antagonist. Dose/Time: Weight-based. Purpose: Adjunct for refractory cholestatic pruritus (limited evidence) and nausea. Mechanism: Central/peripheral serotonin pathway modulation. Side effects: Constipation, QT prolongation risk. Medscape

18. Platelet transfusion (procedure; pharmacologic adjunct)
    Class: Blood product. Dose/Time: Per hematology when bleeding risk is high. Purpose: Manage bleeding due to platelet granule defects. Mechanism: Provides functional platelets. Side effects: Transfusion reactions; use when clearly indicated. PMC

19. Cholestatic bone disease support (calcitriol in select cases)
    Class: Active vitamin D analog (specialist-guided). Dose/Time: Lab-guided. Purpose: Treat severe deficiency/rickets when standard D fails. Mechanism: Directly active form bypasses liver activation. Side effects: Hypercalcemia risk; close monitoring. PMC

20. Experimental/limited evidence agents (IBAT inhibitors)
    Class: Ileal bile-acid transporter inhibitors (e.g., maralixibat/odevixibat). Dose/Time: Not standard for ARC. Purpose: Investigational for pruritus; an ARC small trial report found no benefit. Mechanism: Reduce enterohepatic bile-acid recycling. Side effects: Diarrhea, fat-soluble vitamin loss. Use only in trials/specialist settings. AASLD Conference

---

Dietary (molecular) supplements

These support nutrition in cholestasis and failure to thrive; all require clinician/dietitian oversight and lab monitoring.

1. Water-miscible fat-soluble vitamins (A, D, E, K)
   Dosage: Lab-guided pediatric liver protocols. Function/Mechanism: Compensate for bile-dependent malabsorption; protect vision, bones, nerves, and coagulation. PMC

2. Medium-chain triglyceride oil
   Dosage: As % of total calories per dietitian. Function/Mechanism: Bile-independent energy source; improves weight gain; must balance essential LCTs. Rare Diseases

3. Essential fatty acids (linoleic/α-linolenic acids)
   Dosage: Diet-based or formula add-ons. Function/Mechanism: Prevent EFA deficiency when using high-MCT diets. Rare Diseases

4. Calcium and phosphorus supplementation
   Dosage: Lab-adjusted. Function/Mechanism: Support bone mineralization alongside vitamin D. PMC

5. Magnesium
   Dosage: Lab-guided. Function/Mechanism: Corrects concomitant losses that worsen hypocalcemia and neuromuscular irritability. PMC

6. Iron (if deficient)
   Dosage: Standard pediatric dosing. Function/Mechanism: Restores hemoglobin and improves energy. PMC

7. Folate/B12 (as indicated)
   Dosage: Lab-guided. Function/Mechanism: DNA synthesis and red cell maturation. PMC

8. Zinc
   Dosage: Specialist-guided. Function/Mechanism: Supports growth, appetite, and skin repair; losses can be high in cholestasis. PMC

9. Selenium (select cases)
   Dosage: Micro-trace, lab-guided. Function/Mechanism: Antioxidant enzyme cofactor; deficiency may impair immunity. PMC

10. Water-soluble multivitamin tailored for cholestasis
    Dosage: Per product/weight. Function/Mechanism: Broad micronutrient safety net when intake is limited. PMC

---

Immunity-booster / regenerative / stem-cell” drugs

There is no validated immune-booster or stem-cell drug that reverses ARC. The items below explain current reality to help families avoid misinformation.

1. IVIG (intravenous immunoglobulin)
   Use: Only for specific immune defects or severe infections—not to treat ARC itself. Mechanism: Passive antibodies; does not correct VPS33B/VIPAS39 trafficking defects. Dose: Immunology-guided. Rare Diseases

2. Growth factors (e.g., erythropoietin if anemia of chronic disease)
   Use: Selected cases with specialist guidance. Mechanism: Stimulates red cell production; supportive only. Dose: Hematology-guided. PMC

3. Experimental cell therapies (e.g., mesenchymal stem cells)
   Use: Not established for ARC; outside clinical trials they should not be used. Mechanism: Theoretical anti-inflammatory/trophic effects; no proven clinical benefit in ARC. PMC

4. Gene therapy concepts
   Use: Research stage; no clinical product for ARC. Mechanism: Would need to restore VPS33B/VIPAS39 function in multiple tissues—currently not available. bioRxiv

5. Probiotics
   Use: May aid GI comfort but do not treat ARC mechanism. Mechanism: Gut microbiome modulation; evidence in ARC is lacking. Dose: Pediatric GI-guided. Rare Diseases

6. Omega-3 fatty acids
   Use: Nutritional; may support skin and inflammation balance but not disease-modifying. Mechanism: Membrane lipids/anti-inflammatory mediators. Dose: Dietitian-guided. Rare Diseases

Surgeries / procedures

1. Feeding tube placement (NG/PEG) when oral intake is inadequate
   Why: Secure calories, give medications and vitamins reliably, reduce aspiration risk. Rare Diseases

2. Central venous access (when necessary)
   Why: For reliable labs, transfusions, or parenteral nutrition during severe decompensation—balanced against infection risk. Rare Diseases

3. Orthopedic procedures (select deformities)
   Why: Release severe contractures that block care/positioning; chosen cautiously due to bleeding and wound-healing concerns. Rare Diseases

4. Skin/wound procedures
   Why: Debridement/closure for recurrent breakdowns; prevention focus remains primary. PMC

5. Liver transplantation (very rare, case-by-case)
   Why: Considered for intractable pruritus or liver failure; however, ARC is multisystem—outcomes are uncertain and data are limited to case reports. Decision requires deep multidisciplinary review. ResearchGate

---

Prevention tips

1. Keep a daily log of feeds, weights, diapers, and meds—spot problems early. Rare Diseases

2. Hand hygiene and skin checks to prevent infections. Rare Diseases

3. Vaccinations on schedule, per pediatric guidance. Rare Diseases

4. Avoid overheating; use breathable clothing. AASLD

5. Maintain moisturizing routines to protect skin barrier. PMC

6. Store medications separately from cholestyramine by ≥4 hours. PMC

7. Use safe sleep and pressure-relief positioning. PMC

8. Keep nails short to reduce scratching injury. AASLD

9. Plan clinic follow-ups with hepatology, nephrology, nutrition, and rehab. Rare Diseases

10. Seek genetic counseling for family planning. BioMed Central

---

When to see (or call) doctors urgently

Call your child’s care team or seek urgent care for: fever, poor feeding or vomiting with dehydration signs (few wet diapers, lethargy), worsening jaundice or itching, new or heavy bleeding/bruising, breathing trouble, persistent diarrhea, profound sleepiness, or if medications are refused/vomited repeatedly. Regularly scheduled visits are also needed for growth checks, lab monitoring (electrolytes, liver tests, vitamins), and medication/vitamin adjustments. Rare Diseases +1

---

What to eat and what to avoid

What to emphasize: calorie-dense feeds; pediatric formulas incorporating MCT when fat malabsorption is present; adequate protein; water-miscible fat-soluble vitamins; sufficient calcium, phosphorus, magnesium, and trace elements under dietitian guidance. What to limit/avoid: foods or supplements that interfere with meds (e.g., giving vitamins at the same time as cholestyramine), excessive added sugar that displaces nutrient-dense calories, and unproven “detox” or “immune-boosting” products that may harm the liver. Tailor textures to your child’s swallowing plan. Rare Diseases +1

---

Frequently asked questions

1. Is ARC curable?
   Not yet. Care focuses on symptoms, growth, and preventing complications. Research is active. PMC

2. Which genes cause ARC?
   Most cases involve VPS33B; others involve VIPAS39/VIPAR. Both genes work together in vesicle trafficking. PMC+1

3. How is ARC inherited?
   Autosomal recessive—both parents usually carry one non-working copy; each pregnancy has a 25% chance of an affected child. Rare Diseases

4. Can ARC be mild?
   Yes—some children with certain variants live longer with fewer symptoms, but close follow-up is still essential. Frontiers+1

5. Why is the itch so bad?
   Bile and related molecules build up and activate itch pathways in the skin and nervous system. Frontiers

6. What helps the itch without medicine?
   Cool rooms, loose cotton clothes, moisturizers, short lukewarm baths, and trimmed nails. AASLD

7. What are first medicines for itch?
   Cholestyramine first; rifampin or naltrexone if needed; others case-by-case. AASLD

8. Do new bile-acid drugs (IBAT inhibitors) work in ARC?
   Evidence is insufficient; a small report found no benefit for maralixibat in ARC. AASLD Conference

9. Can liver transplant cure ARC?
   It may help selected liver-specific problems, but ARC is multisystem; published experience is limited and outcomes uncertain. ResearchGate

10. Why are vitamins A, D, E, K so important?
    Cholestasis blocks their absorption, causing bleeding, bone, nerve, and vision problems—so we replace them. PMC

11. Why does my child need bicarbonate or electrolytes?
    Kidney tubules leak bicarbonate and salts; replacing them prevents dehydration and acidosis. PMC

12. Are stem-cell or gene therapies available now?
    No approved therapies yet; research is ongoing. Beware of unproven clinics. bioRxiv

13. Can my child be vaccinated?
    Yes—follow pediatric schedules unless your specialists advise temporary changes for specific reasons. Rare Diseases

14. Is there a support resource for families?
    National Organization for Rare Disorders (NORD) maintains accessible information on ARC. Rare Diseases

15. What specialists should be on the team?
    Pediatric hepatology, nephrology, nutrition/dietetics, rehab (PT/OT/SLP), dermatology, hematology, genetics, and palliative care as needed. Rare Diseases

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 23, 2025.